Hidradenitis suppurativa (HS) is a painful and psychologically distressing disease that requires early diagnosis and treatment. Join Dr Joslyn Kirby and explore:
- Diagnostic techniques and the essential need for earlier diagnosis
- Pathophysiological mechanisms and the burden of HS in our animation
- Current and future treatments in video interviews, and summaries of the latest research into emerging and investigational treatments from key congresses in 2022
Meet Olivia in our animated patient case study below and learn about the importance of staying up to date on the latest developments in HS, the impact of this burdensome disease, and the shifting treatment landscape.
What is known about the complex pathophysiology of hidradenitis suppurativa? Discover the latest research uncovering the mechanisms behind this burdensome disease as well as the prevalence, symptoms, need for early diagnosis, and treatments currently available for HS. Also discover how an understanding of pathophysiology has led to the identification of multiple investigational therapeutic targets for hidradenitis suppurativa.
Explore the latest developments as investigational treatments progress through clinical trials, including key results presented at the 2022 EADV congress
This Learning Zone has been developed by EPG Health with expert insights provided by Dr Joslyn Kirby.
Note: Olivia is a theoretical patient case for educational purposes only1.
EHSF 2024 - Congress highlights
European Hidradenitis Suppurativa Foundation (EHSF) conference report, with a review of diagnosis, surgery, treatment, guideline and clinical trial updates
EADV 2023 highlights
Recap on key HS highlights from EADV 2023 with expert Professor Falk Bechara
Examine the epidemiology, burden, and diagnosis
Learn about unmet needs and treatments
Hear the latest updates on HS from a leading expert
Bitesize publication explainer videos exploring the latest big data in HS
EADV 2022 Highlights
The 2022 European Academy of Dermatology and Venereology Congress began on 7 September in Milan. With daily highlights covering hidradenitis suppurativa (HS) research, diagnosis and treatment, all the latest developments are simply a click away.
Meet the expert
Dr Joslyn Kirby
Dr. Kirby is a dermatologist and clinician-researcher at Penn State Hershey. She earned her medical degree from the University of Virginia, then completed her dermatology residency at the University of Pennsylvania. In her clinical and research work, she is interested in acneiform conditions, especially, hidradenitis suppurativa, including its effects on people, outcome measurement, and pathomechanisms. She is the principal investigator of a number of clinical research trials.
Disclosures: Dr Kirby has been on advisory boards for: AbbVie, Incyte, Novartis and UCB, and has been a consultant for: AbbVie, Alumis, DermTech, Guidepoint, Incyte, Insmed, Janssen, Moonlake, Novartis and UCB. Dr Kirby has also been a speaker for: AbbVie, Novartis, UCB and Janssen.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. The HS publication explainer series was developed in collaboration with the HS Foundation.